Table 2 Comparisons of patient characteristics between the placebo and DBT groups.

From: A prospective, randomized, double-blind, placebo-controlled trial of the Kampo formula daiobotanpito combined with antibiotic therapy for acute diverticulitis

 

DBT group

N = 86

Placebo group

N = 85

Age (years)

48.48 ± 13.39

50.92 ± 11.56

Sex

  

Male

53 (49.5%)

54 (50.5%)

Female

33 (51.6%)

31 (48.4%)

Height (cm)

165.39 ± 9.50

164.66 ± 9.78

BMI (kg/m2)

22.55 ± 3.17

23.69 ± 4.16

Body temperature (℃)

37.28 ± 0.83

37.39 ± 0.77

Laboratory findings

  

WBC count 103/µL

11.20 ± 3.47

12.11 ± 3.25

Neutrophil count (%)

77.54 ± 7.74

77.31 ± 7.36

CRP level (mg/dL)

8.06 ± 5.66

7.09 ± 5.52

History of diverticulitis

  

Present

15 (48.4%)

16 (51.6%)

Abscess

  

Present

9 (60.0%)

6 (40.0%)

Underlying disease

  

Present

9 (33.3%)

18 (66.7%)

Diseased parts

  

Sigmoid colon

20 (23.3%)

14 (16.5%)

Ascending colon

46 (53.5%)

44 (51.8%)

Descending colon

7 (8.1%)

16 (18.8%)

Ileum

1 (1.2%)

2 (2.4%)

Cecum

1 (1.2%)

2 (2.4%)

Transverse colon

4 (4.7%)

3 (3.5%)

Others

7 (8.1%)

4 (4.7%)

Antibiotic type

  

Cefmetazole

56 (65.1%)

54 (63.5%)

Ceftriaxone

8 (9.3%)

9 (10.6%)

Others

22 (25.6%)

22 (25.9%)

  1. BMI: body mass index, CRP: C-reactive protein, DBT: daiobotanpito, WBC, white blood cell.
Back to article page